Patronus Biotech receives ethical approval for phase 1 malaria vaccine trials in Australia
Bellberry Limited has granted ethical clearance for the initial human clinical trials of Patronus Biotech’s multi-stage malaria vaccine candidates.
Patronus Biotech has secured approval from Australia’s Bellberry Limited research ethics committee to initiate phase 1 human clinical trials for its new malaria vaccine candidates. The study marks the first time these multi-stage vaccines, which utilize virus-like particle (VLP) technology, will be tested in human subjects.
The vaccine program focuses on targeting Plasmodium falciparum, the parasite responsible for the most severe forms of malaria globally. By utilizing VLP technology, the company aims to trigger an immune response across multiple stages of the parasite's life cycle, a strategy intended to improve efficacy compared to traditional single-antigen approaches.
The start of these human trials represents a significant milestone for the firm as it moves from laboratory and animal testing to clinical assessment. If successful, the data gathered from this initial phase will inform further research into the efficacy and safety profile of the candidates, potentially advancing the development of a durable malaria prevention tool.